Key Highlights:
- Esperion Therapeutics (ESPR, Financial) stock has declined significantly, falling 15.8% in the past month.
- Despite a Momentum Score of A, a Hold ranking persists due to downward earnings revisions.
- Analyst consensus indicates a strong potential upside, with price targets suggesting a substantial increase from current values.
Esperion Therapeutics Inc. (NASDAQ: ESPR) has recently been on a downward trajectory, with its stock value dropping 15.8% over the last month. This decline contrasts sharply with broader market trends. While the company boasts an impressive Momentum Score of A, its overall VGM Score remains at C, signaling a mixed outlook for investors. Recent downward revisions in earnings estimates have resulted in the stock receiving a Hold ranking, which may concern some investors.
Wall Street Analysts Forecast
Esperion Therapeutics Inc (ESPR, Financial) is currently receiving varied attention from Wall Street analysts, who have provided one-year price targets ranging significantly. The average target price is set at $6.63, with expectations spanning from a high of $16.00 to a low of $2.00. This average target indicates a remarkable potential upside of 591.76% from the current trading price of $0.96. Investors can uncover more detailed estimate data on the Esperion Therapeutics Inc (ESPR) Forecast page.
The consensus among 9 brokerage firms suggests an "Outperform" status for Esperion Therapeutics Inc (ESPR, Financial), with an average brokerage recommendation score of 2.2. This rating, which ranges from 1 (Strong Buy) to 5 (Sell), underscores a generally positive outlook from analysts.
Additionally, according to GuruFocus estimates, the projected GF Value of Esperion Therapeutics Inc (ESPR, Financial) in one year is calculated to be $2.79. This signifies an anticipated upside of 191.32% from the current price of $0.9577. The GF Value represents GuruFocus' determination of the fair trading value, based on historical trading multiples, past business growth, and future performance estimates. Further insights are available on the Esperion Therapeutics Inc (ESPR) Summary page.
